Xenetic Biosciences (XBIO) Depreciation & Amortization (CF) (2011 - 2021)
Xenetic Biosciences' (XBIO) quarterly Depreciation & Amortization (CF) came in at -$26199.0 in Q4 2021, down 37.59% YoY from -$41975.7 in Q4 2020, and down 411.41% on a QoQ basis from $8413.0 in Q1 2021.
Xenetic Biosciences (XBIO) Depreciation & Amortization (CF) (2011 - 2021) Analysis & Trends
Xenetic Biosciences (XBIO) has 10 years of Depreciation & Amortization (CF) data on file, last reported at -$26199.0 in Q4 2021.
- Quarterly Depreciation & Amortization (CF) fell 37.59% year-over-year to -$26199.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was -$26199.0 (down 146.49% YoY) and the FY2020 annual result came in at $1000.0, down 95.71% from the prior year.
- Depreciation & Amortization (CF) retreated to -$26199.0 in Q4 2021, from $8413.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $10179.0 in Q2 2019 to a low of -$26199.0 in Q4 2021.
- A 5-year average of $1978.3 and a median of $5361.5 in 2017 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2019 — Depreciation & Amortization (CF) surged 545.0% — and 2020, when it tumbled 385.96%.
- Tracing XBIO's Depreciation & Amortization (CF) over 5 years: stood at $4447.0 in 2017, then retreated by 26.09% to $3287.0 in 2018, then surged by 102.59% to $6659.0 in 2019, then sank by 385.96% to -$19042.0 in 2020, then plunged by 37.59% to -$26199.0 in 2021.
- The last three Depreciation & Amortization (CF) figures came in at -$26199.0 (Q4 2021), $8413.0 (Q1 2021), and -$19042.0 (Q4 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -26,199.00 |
| Dec 31, 2021 | -26,199.00 |
| Mar 31, 2021 | 8,413.00 |
| Mar 31, 2021 | 8,413.00 |
| Dec 31, 2020 | -19,042.00 |
| Dec 31, 2020 | -19,042.00 |
| Jun 30, 2020 | 200.00 |
| Jun 30, 2020 | 200.00 |
| Mar 31, 2020 | 6,824.00 |
| Mar 31, 2020 | 6,824.00 |
| Dec 31, 2019 | 6,659.00 |
| Dec 31, 2019 | 6,659.00 |
| Sep 30, 2019 | 6,450.00 |
| Sep 30, 2019 | 6,450.00 |
| Jun 30, 2019 | 10,179.00 |
| Jun 30, 2019 | 10,179.00 |
| Dec 31, 2018 | 3,287.00 |
| Dec 31, 2018 | 3,287.00 |
| Sep 30, 2018 | 1,000.00 |
| Sep 30, 2018 | 1,000.00 |